OnKure Therapeutics (NASDAQ:OKUR) Receives $32.33 Consensus PT from Analysts
OnKure Therapeutics (NASDAQ:OKUR – Get Free Report) has earned a consensus recommendation of “Buy” from the six ratings firms that are presently covering the stock, Marketbeat reports. Four equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 12 month target […]
OnKure Therapeutics (NASDAQ:OKUR – Get Free Report) has earned a consensus recommendation of “Buy” from the six ratings firms that are presently covering the stock, Marketbeat reports. Four equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 12 month target […]
